Contact Us

clinical trial

Home
Blog Standard
Tag: clinical trial
Company News
June 18, 2025 Oxford Vacmedix Comments: 0

Patient recruitment completed in OVM-200 Phase 1 trial

The Phase 1 trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been fully recruited in only three months since the new extended dosing protocol was implemented. Oxford, UK – 17th June 2025 Press Release – Patient recruitment fully completed in OVM-200 Phase 1 trial Oxford Vacmedix (OVM) announced today that patient recruitment in the ongoing Phase 1 trial of OVM-200 has been completed.  24 patients have been recruited in Phase 1b bringing the total recruitment, including...
Read More
Sarah Cannon Research Institute
Company News
February 20, 2025 Oxford Vacmedix Comments: 0

First patient treated with new extended dosing of OVM-200 cancer vaccine

Extended dosing of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been approved by the MHRA for use in the ongoing Phase 1 clinical trial Oxford, UK – 20th February 2025 Press Release: First patient treated with new exetended dosing of OVM-200 Oxford Vacmedix (OVM) announced today the first patient being treated with new extended dosing of OVM-200, at the prestigious Sarah Cannon Research Institute in London. The extended dosing protocol was first suggested by the clinical investiga...
Read More
Company News January 9, 2025 Oxford Vacmedix Comments: 0

Innovate UK award to OVM for clinical development of OVM-200

Oxford Vacmedix receives an Investor Partnership award from Innovate UK for the clinical development of lead cancer vaccine OVM-200. Oxford, UK _ 9 January 2025 Press Release – Innovate UK Award 09-Jan-25 Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, confirmed today the grant of a prestigious Investor Partnership award from Innovate UK for the clinical development of its lead cancer vaccine OVM-200. The award is made as part of the SME Round 6 p...
Read More
Company News November 27, 2024 Oxford Vacmedix Comments: 0

UK charity Prostate Cancer Research invests in Oxford Vacmedix Series B

Support from leading Prostate cancer charity for the clinical development of OVM-200. Oxford, UK – 27th November 2024 Press Release – Prostate Cancer Research invests in Oxford Vacmedix Series B Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today Series B investment from Proven Connect, the translational arm of the charity Prostate Cancer Research (PCR). ​ Proven Connect bridges the gap between industry, investors, health prov...
Read More
Company News November 6, 2024 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces lead investment for Series B fund

Lead investment of $3.0 million in Oxford Vacmedix Series B from existing investors. Oxford, UK – 6th November 2024 Press Release – Oxford Vacmedix announces lead investment for Series B fund Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today the lead investment in its Series B fund of $3.0m from existing investors, Dx&Vx of Seoul, South Korea and Mr. Jin of Jia He Hui Investment of Beijing, China. Dx&Vx is OVM’s larges...
Read More
Company News July 31, 2024 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces grant from Innovate UK for OVM-200 clinical trial

Prostate Cancer Research’s Proven Connect supports grant application and facilitates additional funding for the clinical development of OVM’s lead cancer vaccine, OVM-200. Oxford – 31st July 2024 Press Release – Oxford Vacmedix announces grant from Innovate UK for OVM-200 clinical trial Oxford Vacmedix (OVM), developing therapeutic cancer vaccines, announced today the grant of a prestigious non-dilutive Investor Partnership Award from Innovate UK, the UK’s innovation agency, to...
Read More
Company News June 27, 2024 Oxford Vacmedix Comments: 0

Oxford Vacmedix wins 1st prize in 2024 Talent, Innovation and Entrepreurship Competition

Oxford Vacmedix has won the 1st prize in the China Overseas Talents Competition (UK Division)   The UK section of the competition was held in London on 14th June 2024 and Oxford Vacmedix won 1st prize from a strong field of 25 competitors. The international judges were impressed by the company’s groundbreaking ROP (Recombinant Overlapping Peptide) technology and its applications to develop therapeutic vaccines to treat cancer. OVM’s lead cancer vaccine, OVM-200, is in Phase 1 cl...
Read More
Company News March 4, 2024 Oxford Vacmedix Comments: 0

New opportunity for Oxford Vacmedix future clinical development through sale of Head of Clinical Operations, Mark Thomas’ company Clinicology Ltd.

FGK Clinical Research GmbH, announces the successful acquisition of Clinicology Ltd. This strategic move marks a significant milestone for both companies and benefits OVM Oxford, UK – 4th March 2024 Press Release – Sale of Clinicology Ltd. Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today that Clinicology Ltd, the contract research organisation company owned by Mark Thomas, Head of Clinical Operations has been acquired by a Germ...
Read More
Company News January 31, 2024 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces major milestone in clinical development of OVM-200

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable three years post manufacture – a major milestone for OVM’s lead cancer vaccine, OVM-200 Oxford, UK – 31st January 2024 Press Release – OVM-200 major milestone three year stabilty Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today that OVM-200 has been tested and independently certified as stable three years after manufacture. OVM...
Read More
Company News November 28, 2023 Oxford Vacmedix Comments: 0

Licensing deal with Dx&Vx for OVM-200 in South Korea and China

Ongoing discussions at an advanced stage with leading shareholder DxVx, to license OVM-200 for South Korea and for China. Oxford, UK – 28th November 2023 Press Release – Licensing deal with Dx&Vx for OVM-200 in South Korea and China Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today ongoing licensing discussions with its largest shareholder DxVx for lead cancer vaccine OVM-200. If concluded the licensing deal will grant DxVx...
Read More
en_GBEnglish
en_GBEnglish